A Diagnosis of Allergic Contact Dermatitis (ACD) must be strongly considered for patients who present with a chronic or recurrent rash. When the rash is in a clothing (or textile) distribution ...

If you’ve ever fallen down a #SkinTok rabbit hole (guilty), you’ve probably heard of atopic dermatitis (AD ... exercise and ...

AMSTERDAM, Netherlands — For patients with atopic dermatitis (AD) who responded to the anti-interleukin (IL)-13 monoclonal antibody lebrikizumab in the pivotal trials, the level of response ...

But when should you be concerned that it might be atopic dermatitis? Atopic dermatitis, often referred to as eczema, is a ...

When people talk about eczema, they usually mean atopic dermatitis — its most common ... trigger your eczema including dry weather or air, clothing fibers, skin and makeup products, pollutants ...

Education theory and practice go head to head when Professor Dylan Wiliam takes over one Year 8 class to test simple ideas that he believes could improve the quality of education.

Considering taking supplements to treat atopic dermatitis eczema? Below is a list of common natural remedies used to treat or reduce the symptoms of atopic dermatitis eczema. Follow the links to ...

People with moderate-to-severe atopic dermatitis, the most common form of eczema, don’t always get adequate relief from topical treatments like steroid creams and ointments. Now they have a new ...

s (ARQT) ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of atopic dermatitis in individuals regardless of race, ethnicity, and Fitzpatrick skin types ...

Eli Lilly revs up immunology engine as Olumiant cruises toward coveted alopecia green light “Patients still struggle to control their moderate-to-severe atopic dermatitis with currently ...

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 years and older with moderate-to-severe atopic dermatitis. The approval ...

The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD). The FDA approved ...